Kim Rivers runs a company that deals primarily in medical cannabis. Following President Donald Trump’s Dec. 18 move to relax federal restrictions on the drug, Rivers’ Florida-headquartered Trulieve Cannabis Corp. wants to bring a marijuana-based medicine to market – specifically, a “time-release product” intended for sufferers of Parkinson’s disease.
Great leaps forward in medicine and science are expected when marijuana is officially Schedule 3. But classifying cannabis with drugs like anabolic steroids and Tylenol with codeine has another profound benefit. Only with cannabis research will advocates get what they want and see cannabis descheduled – and then, eventually, legalized nationally, business leaders and advocates say.
ADVERTISEMENT
“Everybody talks about Schedule 3 from a tax perspective,” said Boris Jordan, the chairman and founder of competing
Read full article on Marijuana Business Daily
